Guggenheim Capital’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-21,572
Closed -$45.7K 1895
2023
Q3
$45.7K Sell
21,572
-35,287
-62% -$117K ﹤0.01% 1829
2023
Q2
$271K Sell
56,859
-738
-1% -$4.07K ﹤0.01% 1689
2023
Q1
$328K Sell
57,597
-63,320
-52% -$382K ﹤0.01% 1653
2022
Q4
$1.22M Sell
120,917
-6,301
-5% -$118K 0.01% 1059
2022
Q3
$2.85M Sell
127,218
-12,756
-9% -$369K 0.03% 709
2022
Q2
$3.47M Buy
139,974
+7,599
+6% +$210K 0.03% 689
2022
Q1
$5.13M Sell
132,375
-24,513
-16% -$949K 0.03% 641
2021
Q4
$9.18M Buy
156,888
+17,225
+12% +$976K 0.05% 459
2021
Q3
$8.28M Buy
139,663
+35,489
+34% +$2.78M 0.05% 454
2021
Q2
$9.04M Sell
104,174
-1,756
-2% -$142K 0.05% 430
2021
Q1
$8.73M Buy
105,930
+13,522
+15% +$1.3M 0.06% 412
2020
Q4
$8.4M Buy
92,408
+34,100
+58% +$2.12M 0.05% 394
2020
Q3
$2.33M Sell
58,308
-250
-0.4% -$8.73K 0.02% 825
2020
Q2
$2.01M Buy
58,558
+24,690
+73% +$736K 0.02% 882
2020
Q1
$752K Buy
33,868
+13,903
+70% +$352K 0.01% 1211
2019
Q4
$391K Buy
19,965
+7,312
+58% +$116K ﹤0.01% 1699
2019
Q3
$197K Buy
+12,653
New +$243K ﹤0.01% 2007
2017
Q4
Sell
-10,636
Closed -$43K 2742
2017
Q3
$43K Buy
10,636
+336
+3% +$1.14K ﹤0.01% 2707
2017
Q2
$33K Buy
+10,300
New +$39.5K ﹤0.01% 2754

Other funds holding FATE